(Q24243613)

English

Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease

scientific article

In more languages

Statements

scholarly article

0 references

0 references

1 reference

Europe PubMed Central

Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease (English)

0 references

chronic obstructive pulmonary disease

0 references

Phillippa Poole

4

object named as

P Poole

author given names

P

author last names

Poole

1 reference

30 October 2023

author name string

Luis Javier Nannini

1

author given names

L J

author last names

Nannini

1 reference

30 October 2023

Christopher J Cates

2

author given names

C J

author last names

Cates

1 reference

30 October 2023

Toby J Lasserson

3

author given names

T J

author last names

Lasserson

1 reference

30 October 2023

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 October 2007

0 references

Cochrane Database of Systematic Reviews

0 references

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

The TORCH (towards a revolution in COPD health) survival study protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Relationship between respiratory symptoms and medical treatment in exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Patient's perception of exacerbations of COPD--the PERCEIVE study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Toward a consensus definition for COPD exacerbations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

21 January 2018

Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

7 January 2021

based on heuristic

inferred from DOI database lookup

Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

7 January 2021

based on heuristic

inferred from DOI database lookup

Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

7 January 2021

based on heuristic

inferred from DOI database lookup

Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006829

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD006829

1 reference

https://api.fatcat.wiki/v0/release/kpij2nitezbhvdchzsbm4ehmdi

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_kpij2nitezbhvdchzsbm4ehmdi

1 reference

https://api.fatcat.wiki/v0/release/kpij2nitezbhvdchzsbm4ehmdi

30 July 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/kpij2nitezbhvdchzsbm4ehmdi

30 July 2022

based on heuristic

mapped directly with Wikidata item

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24243613&oldid=2001038146"